Targeting therapy for breast carcinoma by ATP synthase inhibitor aurovertin b

Journal of Proteome Research

Volumn 7, Issue 4, 2008, Pages 1433-1444

  Huang, Tsui Chin ^a   Chang, Hsin Yi ^a   Hsu, Chun Hua ^a   Kuo, Wen Hung ^a   Chang, King Jen ^a   Juan, Hsueh Fen ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; ATP synthase; Aurovertin B; Breast carcinoma; Cell cycle arrest; Proteomic analysis; Targeting therapy

Indexed keywords

AUROVERTIN; AUROVERTIN B; UNCLASSIFIED DRUG; 3,3',4,5'-TETRAHYDROXYSTILBENE; ATP5B PROTEIN, HUMAN; ENZYME INHIBITOR; MEMBRANE PROTEIN; PICEATANNOL; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; RESVERATROL; STILBENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER TISSUE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; APOPTOSIS; BREAST TUMOR; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL STRUCTURE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; FEMALE; IC 50; METABOLISM; PATHOLOGY; TUMOR CELL LINE; UPREGULATION;

APOPTOSIS; AUROVERTINS; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENZYME INHIBITORS; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MEMBRANE PROTEINS; MITOCHONDRIAL PROTON-TRANSLOCATING ATPASES; MODELS, MOLECULAR; STILBENES; UP-REGULATION;

EID: 45549099294     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr700742h     Document Type: Article

References (50)

1. Smigal, C.; Jemal, A.; Ward, E.; Cokklnides, V.; Smith, R.; Howe, H. L.; Thun, M. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J. Clin. 2006, 56, 168-183.
2. Gupta, V.; Harkin, D. P.; Kawakubo, H.; Maheswaran, S. Transforming Growth Factor-beta superfamily: evaluation as breast cancer biomarkers and preventive agents. Curr. Cancer Drug Targets 2004, 4, 165-182.
3. Seidman, A. D. Systemic treatment of breast cancer. Two decades of progress. Oncology (Williston Park) 2006, 20, 983-990, discussion 99-82, 99-88.
4. Hsieh, A. C.; Moasser, M. M. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br. J. Cancer 2007, 97, 453-457.
5. Wang, X. F.; Birringer, M.; Dong, L. F.; Veprek, P.; Low, P.; Swettenham, E.; Stantic, M.; Yuan, L. H.; Zobalova, R.; Wu, K.; Ledvina, M.; Ralph, S. J.; Neuzil, J. A peptide conjugate of vitamin E succinate targets breast cancer cells with high ErbB2 expression. Cancer Res. 2007, 67, 3337-3344.
6. Fernandez Madrid, F. Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis. Cancer Lett. 2005, 230, 187-198.
7. Duffy, M. J. Predictive markers in breast and other cancers: a review. Clin. Chem. 2005, 51, 494-503.
8. Gross, J. M.; Yee, D. How does the estrogen receptor work. Breast Cancer Res. 2002, 4, 62-64.
9. Cui, X.; Schiff, R.; Arpino, G.; Osborne, C. K.; Lee, A. V. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J. Clin. Oncol. 2005, 23, 7721-7735.
10. Castiglioni, F.; Terenziani, M.; Carcangiu, M. L.; Miliano, R.; Aiello, P.; Bertola, L.; Triulzi, T.; Gasparini, P.; Camerini, T.; Sozzi, G.; Fossati-Bellani, F.; Menard, S.; Tagliabue, E. Radiation effects on development of HER2-positive breast carcinomas. Clin. Cancer Res. 2007, 13, 46-51.
11. Prowell, T. M.; Armstrong, D. K. Selecting endocrine therapy for breast cancer: what role does HER-2/neu status play. Semin. Oncol. 2006, 33, 681-687.
12. Griffiths, D. E.; Houghton, R. L. Studies on energy-linked reactions: modified mitochondrial ATPase of oligomycin-resistant mutants of Saccharomyces cerevisiae. Eur. J. Biochem. 1974, 46, 157-167.
13. Haslam, J. M.; Proudlock, J. W.; Linnane, A. W. Biogenesis of mitochondria. 20. The effects of altered membrane lipid composition on mitochondrial oxidative phosphorylation in Saccharomyces cerevisiae. J. Bioenerg 1971, 2, 351-370.
14. Yamamoto, K.; Shimizu, N.; Obi, S.; Kumagaya, S.; Taketani, Y.; Kamiya, A.; Ando, J. Involvement of cell surface ATP synthase in flow-induced ATP release by vascular endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2007, 293, H1646-1653.
15. Kenan, D. J.; Wahl, M. L. Ectopic localization of mitochondrial ATP synthase: a target for anti-angiogenesis intervention. J. Bioenerg. Biomembr. 2005, 37, 461-465.
16. Chi, S. L,; Pizzo, S. V. Angiostatin is directly cytotoxic to tumor cells at low extracellular pH: a mechanism dependent on cell surface-associated ATP synthase. Cancer Res. 2006, 66, 875-882.
17. Burrell, H. E.; Wlodarski, B.; Foster, B. J.; Buckley, K. A.; Sharpe, G. R.; Quayle, J. M.; Simpson, A. W.; Gallagher, J. A. Human keratinocytes release ATP and utilize three mechanisms for nucleotide interconversion at the cell surface. J. Biol. Chem. 2005, 280, 29667-29676.
18. Kim, B. W.; Choo, H. J.; Lee, J. W.; Kim, J. H.; Ko, Y. G. Extracellular ATP is generated by ATP synthase complex in adipocyte lipid rafts. Exp. Mol. Med. 2004, 36, 476-485.
19. Arakaki, N.; Nagao, T.; Niki, R.; Toyofuku, A.; Tanaka, H.; Kuramoto, Y.; Emoto, Y.; Shibata, H.; Magota, K.; Higuti, T. Possible role of cell surface H+ -ATP synthase in the extracellular ATP synthesis and proliferation of human umbilical vein endothelial cells. Mol. Cancer Res. 2003, 1, 931-939.
20. Das, B.; Mondragon, M. O.; Sadeghian, M.; Hatcher, V. B.; Norin, A. J. A novel ligand in lymphocyte-mediated cytotoxicity: expression of the beta subunit of H+ transporting ATP synthase on the surface of tumor cell lines. J. Exp. Med. 1994, 180, 273-281.
21. Martinez, L. O.; Jacquet, S.; Esteve, J. P.; Rolland, C.; Cabezon, E.; Champagne, E.; Pineau, T.; Georgeaud, V.; Walker, J. E.; Terce, F.; Collet, X.; Perret, B.; Barbaras, R. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL en-docytosis. Nature 2003, 421, 75-79.
22. Moser, T. L.; Kenan, D. J.; Ashley, T. A.; Roy, J. A.; Goodman, M. D.; Misra, U. K.; Cheek, D. J.; Pizzo, S. V. Endothelial cell surface FIFO ATP synthase is active in ATP synthesis and is inhibited by Angiostatin. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 6656-6661.
23. Chang, S. Y.; Park, S. G.; Kim, S.; Kang, C. Y. Interaction of the C-terminal domain of p43 and the alpha subunit of ATP synthase. Its functional implication in endothelial cell proliferation. J. Biol. Chem. 2002, 277, 8388-8394.
24. Scotet, E.; Martinez, L. O.; Grant, E.; Barbaras, R.; Jeno, P.; Guiraud, M.; Monsarrat, B.; Saulquin, X.; Maillet, S.; Esteve, J. P.; Lopez, F.; Perret, B.; Collet, X.; Bonneville, M.; Champagne, E. Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface Fl-ATPase-related structure and apolipoprotein A-I. Immunity 2005, 22, 71-80.
25. Burwick, N. R.; Wahl, M. L.; Fang, J.; Zhong, Z.; Moser, T. L.; Li, B.; Capaldi, R. A.; Kenan, D. J.; Pizzo, S. V. An Inhibitor of the Fl subunit of ATP synthase (IF 1) modulates the activity of Angiostatin on the endothelial cell surface. J. Biol. Chem. 2005, 280, 1740-1745.
26. Juan, H. F.; Wang, I. H.; Huang, T. C.; Li, J. J.; Chen, S. T.; Huang, H. C. Proteomics analysis of a novel compound: cyclic RGD in breast carcinoma cell line MCF-7. Proteomics 2006, 6, 2991-3000.
27. Fiser, A.; Sali, A. Modeller: generation and refinement of homology- based protein structure models. Methods Enzymol. 2003, 374, 461-491.
28. Mpamhanga, C. P.; Chen, B.; McLay, I. M.; Ormsby, D. L.; Lindvall, M. K. Retrospective docking study of PDE4B ligands and an analysis of the behavior of selected scoring functions. J Chem. Inf. Model 2005, 45, 1061-1074.
29. van Raaij, M. J.; Abrahams, J. P.; Leslie, A. G.; Walker, J. E. The structure of bovine Fl-ATPase complexed with the antibiotic inhibitor aurovertin B. Proc. Natl. Acad. Sci U.S.A. 1996, 93, 6913-6917.
30. Venkatachalam, C. M.; Jiang, X.; Oldfield, T.; Waldman, M. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J. Mol. Graph. Model 2003, 21, 289-307.
31. Krammer, A.; Kirchhoff, P. D.; Jiang, X.; Venkatachalam, C. M.; Waldman, M. LigScore: a novel scoring function for predicting binding affinities. J. Mol. Graph. Model. 2005, 23, 395-407.
32. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMM: A program for macro-molecular energy minimization, and dynamics calculations. J. Com-put. Chem. 1983, 4, 187-217.
33. Huang, T. C.; Huang, H. C.; Chang, C. C.; Chang, H. Y.; Ou, C. H.; Hsu, C. H.; Chen, S. T.; Juan, H. F. An apoptosis-related gene network induced by novel compound-cRGD in human breast cancer cells. FEBS Lett. 2007, 581, 3517-3522.
34. Camacho-Carvajal, M. M.; Wollscheid, B.; Aebersold, R.; Steimle, V.; Schamel, W. W. Two-dimensional Blue native/SDS gel electrophoresis of multi-protein complexes from whole cellular lysates: a proteomics approach. Mol. Cell Proteomics 2004, 3, 176-182.
35. Issaq, H. J.; Veenstra, T. D.; Conrads, T. P.; Felschow, D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem. Biophys. Res. Commun. 2002, 292, 587-592.
36. Sethuraman, M,; McComb, M. E.; Huang, H.; Huang, S.; Heibeck, T.; Costello, C. E.; Cohen, R. A. Isotope-coded affinity tag (ICAT) approach to redox proteomics: identification and quantitation of oxidant-sensitive cysteine thiols in complex protein mixtures. J. Proteome Res. 2004, 3, 1228-1233.
37. Yang, Y.; Thannhauser, T. W.; Li, L.; Zhang, S. Development of an integrated approach for evaluation of 2-D gel image analysis: Impact of multiple proteins in single spots on comparative proteomics in conventional 2-D gel/MALDI workflow. Electrophoresis 2007, 28, 2080-2094.
38. Bondar, O. P.; Barnidge, D. R.; Klee, E. W.; Davis, B. J.; Klee, G. G. LC-MS/MS quantification of Zn-alpha2 glycoprotein: a potential serum biomarker for prostate cancer. Clin. Chem. 2007, 53, 673-678.
39. Huang, H. L.; Stasyk, T.; Morandell, S.; Dieplinger, H.; Falkensammer, G.; Griesmacher, A.; Mogg, M.; Schreiber, M.; Feuerstein, I.; Huck, C. W.; Stecher, G.; Bonn, G. K.; Huber, L. A. Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/ MALDI-TOF/TOF and data validation by routine clinical assays. Electrophoresis 2006, 27, 1641-1650.
40. Li, H.; Desouza, L. V.; Ghanny, S.; Li, W.; Romaschin, A. D.; Colgan, T. J. O. A.; Siu, K. W. Identification of candidate biomarker proteins released by human endometrial and cervical cancer cells using two-dimensional liquid chromatography/tandem mass spectrometry. J. Proteome Res. 2007, 6, 2615-2622.
41. Srivastava, S.; Srivastava, R. G. Proteomics in the forefront of cancer biomarker discovery. J. Proteome Res. 2005, 4, 1098-1103.
42. Zhang, H.; Kong, B.; Qu, X.; Jia, L.; Deng, B.; Yang, Q. Biomarker discovery for ovarian cancer using SELDI-TOF-MS. Gynecol. Oncol. 2006, 102, 61-66.
43. Lenaz, G. Effect of aurovertin on energy-linked processes related to oxidative phosphorylation. Biochem. Biophys. Res. Commun. 1965, 21, 170-175.
44. Rognan, D. Chemogenomic approaches to rational drug design. Br. I. Pharmacol. 2007, 152, 38-52.
45. Chou, K. C. Structural bioinformatics and its impact to biomedical science. Curr. Med. Chem. 2004, 11, 2105-2134.
46. Scapin, G. Structural biology and drug discovery. Curr. Pharm. Des. 2006, 12, 2087-2097.
47. Jain, A. N. Virtual screening in lead discovery and optimization. Curr. Opin. Drug Discov. Devel. 2004, 7, 396-403.
48. Kitchen, D. B.; Decornez, H.; Furr, J. R.; Bajorath, J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat. Rev. Drug Discov. 2004, 3, 935-949.
49. Alonso, H.; Bliznyuk, A. A.; Gready, J. E. Combining docking and molecular dynamic simulations in drug design. Med. Res. Rev. 2006, 26, 531-568.
50. DeLano, W. L. The PyMOL Molecular Graphics System. DeLano Scientific: San Carlos, CA, 2002.